Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | ATR | Q13535 | 19/20 | 0.54 |
| ▸ | PRKDC | P78527 | 5/20 | 0.54 |
| ▸ | ATM | Q13315 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557518 | 0.84 | ATR (0.58) | KCNH2ATRPRKDCATM | |
| SCHEMBL15308507 | 0.83 | KCNH2 (0.60) | KCNH2ATRPRKDCATM | |
| SCHEMBL17657838 | 0.82 | KCNH2 (0.59) | KCNH2ATRPRKDCATM | |
| SCHEMBL12078250 | 0.81 | KCNH2 (0.45) | KCNH2ATRPRKDCATM | |
| SCHEMBL17718278 | 0.79 | KCNH2 (0.60) | KCNH2ATRPRKDCATM | |
| SCHEMBL12198422 | 0.79 | ATR (0.48) | ATR | |
| SCHEMBL30977050 | 0.78 | ATR (0.70) | KCNH2ATRPRKDCATM | |
| SCHEMBL16425220 | 0.78 | KCNH2 (0.69) | KCNH2ATRPRKDCATM | |
| SCHEMBL2486014 | 0.78 | ATR (0.70) | KCNH2ATRPRKDCATM | |
| SCHEMBL12077358 | 0.78 | KCNH2 (0.51) | KCNH2ATRPRKDCATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2814820-B1 | ANTI-MALARIAL AGENTS | UNIV CAPE TOWN (ZA) | 2016-07-20 | — | — | EP | claimed |
| EP-2814820-A1 | ANTI -MALARIAL AGENTS | University Of Cape Town (ZA) | 2014-12-24 | — | — | EP | claimed |
| WO-2013121387-A1 | ANTI -MALARIAL AGENTS | UNIVERSITY OF CAPE TOWN (ZA) | 2013-08-22 | — | — | WO | claimed |
| EP-2814820-B1 | ANTI-MALARIAL AGENTS | UNIV CAPE TOWN (ZA) | 2016-07-20 | — | — | EP | disclosed |
| EP-2814820-B1 | ANTI-MALARIAL AGENTS | UNIV CAPE TOWN (ZA) | 2016-07-20 | — | — | EP | disclosed |
| US-9266842-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-02-23 | — | — | US | disclosed |
| US-9266842-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-02-23 | — | — | US | disclosed |
| US-9266842-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2016-02-23 | — | — | US | disclosed |
| US-9062008-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062008-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062008-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-23 | — | — | US | disclosed |
| EP-2569286-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013121387-A1 | ANTI -MALARIAL AGENTS | UNIVERSITY OF CAPE TOWN (ZA) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013121387-A1 | ANTI -MALARIAL AGENTS | UNIVERSITY OF CAPE TOWN (ZA) | 2013-08-22 | — | — | WO | disclosed |
| EP-2569286-A2 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20120035408-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035408-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035408-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-09 | — | — | US | disclosed |
| WO-2011143423-A2 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143423-A2 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035408-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | KCNH2 2655/4885ATR 1/4885PRKDC 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.